PLUS THERAPEUTICS, INC. CYTX Cash Flow

Plus therapeutics, inc. (CYTX)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows used in operating activities:
Net loss
-1,087	884	526	-9,147	-3,150	-2,236	-2,330	-3,659	-4,409	-4,287	-4,806	-6,049	-7,544	-4,919	-5,384	-6,404	-5,339	-2,763	1,528	4,449	-21,958	-5,756	-9,384	-11,828	-10,400	-10,040	-5,260	-3,210	-7,667	-3,824	-11,247	-7,883	-9,325	-6,907	-8,335	-5,137	-12,072
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
94	118	161	174	443	539	490	478	497	533	566	610	442	388	220	283	291	332	251	297	213	254	181	184	160	461	509	460	200	221	259	233	220	234	221	206	194
Amortization of deferred financing costs and debt discount
122	196	97	89	168	195	171	107	105	127	162	199	219	240	246	236	232	265	214	243	257	259	399	281	281	288	275	138	192	224	236	233	237	240	0	231	240
Noncash lease expenses
4	-10	-17	39	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for expired inventory
-	-	-	-	-	-	-	-	-	-	-	-	340	146	0	26	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrants
-1,667	-3,476	561	-282	-210	-557	-1,676	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture acquisition obligation accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-203	-217	-217	-145	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,471
Change in fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15,444	134	-134	0	0	-	-	-	-	-	-	-	-	60	570	400	-290
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	84	334	-	-863	-251	-130	-	-	-	-
Change in fair value of option liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,500	-250	-	-300	-460	270	-	-	-	-
Share-based compensation expense
12	21	29	28	49	30	86	96	143	165	178	211	199	155	280	328	317	424	471	687	459	535	1,118	761	687	885	885	965	873	997	930	1,035	942	738	857	840	881
Equity loss from investment in joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-48	-37	-42	-36	-50	-56	-51	-56	-46
Loss on asset disposal
-	-	-	-	-	-13	-3	2	-22	51	10	-17	-2	129	0	0	-2	-3	-5	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture acquisition obligation accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	7	17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-42	290	371	465	203	750	101	87	45	80	43	-24	209	39	214	21
Provision for excess inventory
-	-	-	-	-	30	35	72	326	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable
-191	-3,648	4,823	-184	212	-143	42	-473	747	-138	-582	-74	-335	270	-25	89	-155	-197	413	2	-546	448	-1,119	-1,337	-49	1,570	501	6	-868	2,508	-440	601	-859	502	-455	901	-278
Inventories
0	15	-39	-219	-16	140	-244	-230	-141	206	-298	-152	-7	-281	-570	174	206	-500	740	-630	-100	-343	632	-25	551	-516	159	339	477	-236	303	-266	56	-835	262	339	174
Other current assets
-405	463	-36	-200	-16	429	-170	-43	-301	309	-452	671	65	-428	-68	-545	408	379	152	-364	470	-529	-40	-113	172	93	-96	-1	28	71	-25	-20	298	-	-	-	-
Other assets
-14	35	-41	-256	-1	-16	-8	-23	24	168	-31	-19	-24	796	2	-245	211	399	-355	-339	-68	-135	-157	660	-379	737	-470	-387	974	90	1	-39	22	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-147	-115	130
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-141	-17	922
Accounts payable and accrued expenses
410	67	-1	311	-405	-258	-109	-609	-556	-71	-1,552	290	-484	340	-582	-607	176	175	-219	951	138	-481	-790	-227	351	671	-801	244	-523	929	522	-185	-83	-1,040	-488	946	-854
Deferred revenues
0	0	0	54	-25	-20	-30	39	84	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
0	-101	0	15	39	41	-10	-12	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-638	-469	0	-2,413	0	-3,223	0	0	1,231
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-7	1	12	0	-9	5	-4	-38	-110	130	21	-147	47	165	-165	22	-45	3	-1,203	-2,512	-149	120	-68	-	-	-	-
Long-term deferred rent
-	-	-	-	-	-	-	-	-	-	-16	119	0	-25	-69	-78	-80	-79	-71	-88	-51	-71	16	-51	-46	-44	-30	-4	32	72	84	102	-6	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-4,827	-4,161	-4,637	-5,677	-5,058	-4,522	-6,158	-4,758	-5,030	-4,956	-7,237	-9,175	-8,962	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-154	-45	10
Long-term deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-94	12	12
Net cash used in operating activities
-1,502	1,036	-2,118	-1,554	-3,270	-2,488	-2,647	-2,721	-4,119	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,294	-	-7,919	-8,244	-7,714	-7,899	-7,892	-8,968	-10,564
Cash flows used in investing activities:
Purchases of property and equipment
11	59	2	0	6	5	50	25	53	-	176	90	5	-43	5	36	69	67	47	310	187	-28	325	180	287	-17	104	351	81	127	191	861	25	102	25	302	131
Expenditures for intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	100	155	0	0	0	0	-	-	-	-	-	-	-	-
License agreement termination fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	200	200	200	200	200	200	0	0	0	0	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-1,163	174	-5	-36	-69	-56	-47	-323	-187	104	-325	-480	-642	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-11	2,789	-2	2,789	-6	-5	-50	-25	-53	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-281	-127	-191	-861	-25	-102	-25	-302	-131
Cash flows (used in) provided by financing activities:
Principal payments of long-term obligations
-	-	-	-	-	-	-	-	-	0	1,180	1,770	1,770	0	0	0	0	-	-	-	-	-	-	-	-	12	0	19,807	2,485	2,482	70	69	71	69	2,230	2,230	0
Payment of financing lease liability
18	56	47	0	28	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture purchase payments
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,274	500	0	500	1,000	123	26	47	51	2,138	80	71	70	0	-	-	-	-	-	-	-	-
Proceeds from exercise of employee stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85	4,033	0	33	78	32	115	0	425	37	4	947	-	-	-	-
Proceeds from exercise of employee stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93	2,082	674
Proceeds from sale of common stock, net
0	0	13,980	65	1,919	-6,246	6,446	-50	-150	-	-	9,790	1,435	3,765	-477	17,617	562	2,305	1,819	20,956	3,974	351	-15	9,665	9,000	14,999	0	0	3,001	20,007	0	550	4,396	4,248	9,038	0	0
Costs from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	184	1,418	0	8	56	59	135	0	0
Dividends paid on preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3	72	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-335	1,681	-477	16,343	62	-54	1,319	15,753	3,779	11,697	2,668	9,614	6,895	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-18	-3,107	14,424	-577	1,891	922	6,446	-50	-150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	332	-	-33	477	5,216	4,120	15,491	-148	674
Effect of exchange rate changes on cash and cash equivalents
0	0	0	0	-4	26	-22	-27	39	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-1,531	718	12,304	658	-1,389	-1,545	3,727	-2,823	-4,283	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	20	-58	1	54	85	0	14	-29	15	-72	-17	1	3	-2	-23	-11	-70	0	0	0	0	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-6,305	-2,364	-5,118	10,684	-4,980	-4,632	-4,872	10,643	-1,423	6,773	-4,911	-40	-2,706	5,301	-3,416	-2,783	-9,313	8,089	-8,143	-8,628	-2,523	-3,881	7,574	-9,418	-10,021
Supplemental disclosure of cash flows information:
Cash paid during period for:
Interest
227	117	245	479	347	341	341	338	311	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	-	-	384	405	408	405	400	387	405	590	612	616	654	659	659	660	441	631	520	591	649	632	625	573	469	490	499
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common
-	-	-	-	-	-	-	0	4	23	0	0	0	-	-	-	-	0	0	0	10	16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Declared dividend related to preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3	72	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Capital equipment lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-6	-9	-7	101
Net increase in purchases of property and equipment included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	795	-	-	-	-
Net increase in purchases of property and equipment included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0